Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2013, Vol. 33 Issue (7): 25-30    DOI:
    
Preparation and Immunogenicity of Streptococcus Suis Oral Vaccine in Mice
ZHANG Qiu-xiang1, HOU Hui-li2, LU Ying2, CHEN Wei1, ZHONG Jin2
1. State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, Wuxi 214122, China;
2. Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
Download: HTML   PDF(1086KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  To prevent Streptococcus suis infection, new S. suis oral vaccines were constructed. The virulence factors EF and MRP were first expressed in Escherichia coli BL21 (DE3) pLysS and purified by His-tag. Anti-EF and Anti-MRP polyclonal antibody were prepared by injection of EF and MRP proteins into specific pathogen free mice. Then ef and mrp genes were led by constitutive promoter P59 and signal peptide USP45, subcloned into an expression vector pMG36e and then introduced to Lactobacillus casei ATCC 27092. Western blot showed that EF and MRP proteins were both successfully expressed in L. casei. The production of EF increased gradually, while the expression level of MRP reached a peak when the optical density at 600nm of the recombinant culture was 0.8. The recombinant strains were administered to C57BL/6J mice orally and survived in the intestinal tract of mice for at least 2 days. Expression of EF and MRP in the food-grade vehicle lactic acid bacterium could induce specific anti-EF and anti-MRP antibodies, suggesting it might be a new way to the treatment of s. suis.

Key wordsStreptococcus suis      Lactobacillus casei      Lactic acid bacteria      Vaccine     
Received: 10 December 2012      Published: 25 July 2013
ZTFLH:  Q939  
Cite this article:

ZHANG Qiu-xiang, HOU Hui-li, LU Ying, CHEN Wei, ZHONG Jin. Preparation and Immunogenicity of Streptococcus Suis Oral Vaccine in Mice. China Biotechnology, 2013, 33(7): 25-30.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2013/V33/I7/25

[1] Adrover M F, Guyot-Revol V, Cheli V T, et al. Hippocampal infection with HSV-1-derived vectors expressing an NMDAR1 antisense modifies behavior. Genes, Brain, and Behavior 2003, 2(2):103-113.
[2] Le Loir Y, Azevedo V, Oliveira S C, et al. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microbial Cell Factories, 2005, 4(1):2.
[3] Lun S, Perez-Casal J, Connor W, et al. Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microbial Pathogenesis, 2003, 34(1):27-37.
[4] Staats J J, Plattner B L, Stewart G C, et al. Presence of the Streptococcus suis suilysin gene and expression of MRP and EF correlates with high virulence in Streptococcus suis type 2 isolates. Veterinary Microbiology, 1999, 70(3-4):201-211.
[5] Pallares F J, Schmitt C S, Roth J A, et al. Evaluation of a ceftiofur-washed whole cell Streptococcus suis bacterin in pigs. Canadian journal of veterinary research-Revue canadienne de recherche veterinaire 2004, 68(3):236-240.
[6] Zhang Q, Zhong J, Huan L. Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination. Microbiological Research, 2011, 166(2):111-120.
[7] Parlane N A, Grage K, Lee J W, et al. Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain. Applied and Environmental Microbiology, 2011, 77(24):8516-8522.
[8] Dieye Y, Usai S, Clier F, et al. Design of a protein-targeting system for lactic acid bacteria. Journal of Bacteriology, 2001, 183(14):4157-4166.
[9] Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press, 2001.
[10] Berthier F, Zagorec M, Champomier-Verges M, et al. Efficient transformation of Lactobacillus sake by electroporation. Microbiology, 1996, 142:1273-1279.
[11] 陈思维, 钟瑾, 还连栋. 人胰岛素基因在乳酸菌中的表达及其对非肥胖糖尿病(NOD)小鼠的作用. 微生物学报, 2007, 47:987-991. Chen S, Zhong J, Huan L.Expression of human insulin in lactic acid bacteria and its oral administration in non-obese diabetic mice. Acta Microbiologica Sinica, 2007, 47:987-991.
[12] Nouaille S, Ribeiro L A, Miyoshi A, et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genetics and Molecular Research: GMR, 2003, 2(1):102-111.
[13] Enouf V, Langella P, Commissaire J, et al. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Applied and Environmental Microbiology, 2001, 67(4):1423-1428.
[1] XIAO Yun-xi,ZHANG Jun-he,YANG Wen-wen,CHENG Hong-wei. Research Progress of Human Diploid Cells for Vaccine Production[J]. China Biotechnology, 2021, 41(11): 74-81.
[2] ZHU Xiao-jing,WANG Rui,ZHANG Xin-xin,JIN Jia-xin,LU Wen-long,DING Da-shun,HUO Cui-mei,LI Qing-mei,SUN Ai-jun,ZHUANG Guo-qing. Construction of MDV Recombinant Vaccine Strain Integrated F Gene Using Bacterial Artificial Chromosome Technique[J]. China Biotechnology, 2021, 41(10): 33-41.
[3] DENG Ting-shan,WU Guo-gan,SUN Yu,TANG Xue-ming. Advances in Biosynthesis of Phenyllactic Acid[J]. China Biotechnology, 2020, 40(9): 62-68.
[4] CHENG Xu,YANG Yu-qing,WU Sai-nan,HOU Qin-long,LI Yong-mei,HAN Hui-ming. Construction of DNA Vaccines of Staphylococcus aureus SarA, IcaA and Their Fusion Genes and Preliminary Study in Mouse Immune Response[J]. China Biotechnology, 2020, 40(7): 41-50.
[5] LIU Zhen-zhen,TIAN Da-yong. Development of Sucrose Density Gradient Centrifugation Purification Process for Rabies Vaccine[J]. China Biotechnology, 2020, 40(4): 25-33.
[6] QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.
[7] XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.
[8] JING Hui-yuan,DUAN Er-zhen,DONG Wang. In Vitro Transcribed Self-amplifying mRNA Vaccines[J]. China Biotechnology, 2020, 40(12): 25-30.
[9] LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.
[10] FENG Xue-jiao,HOU Hai-long,YU Qiong,WANG Jun-shu. Market Analysis and Countermeasures of Cervical Cancer Vaccine in China[J]. China Biotechnology, 2020, 40(11): 96-101.
[11] Yan GAO,Jing-jing DU,Bin WANG,Qi LIU,Zhi-qiang SHEN. Study on β-Propiolactone in Inactivation Process of Rabies Vaccine by Gas Chromatography[J]. China Biotechnology, 2019, 39(6): 25-31.
[12] Lin YANG,Zhe-yan FU,Zheng-bing LV,Jian-hong SHU. Classification and Mechanism of Immune Adjuvant[J]. China Biotechnology, 2019, 39(5): 114-119.
[13] Jia-yue XU,Zi-qian LI,Ge ZHANG. Advanced in Research Dengue Virus 3'UTRΔ30 Series Vaccines[J]. China Biotechnology, 2019, 39(3): 97-104.
[14] Fu-lan GAO,Jia-long QI,Cong-yan SHU,Hang-hang XIE,Wei-wei HUANG,Cun-bao LIU,Xu YANG,Wen-jia SUN,Hong-mei BAI,Yan-bing MA. Efficient Secretory Expression of Optimized Mouse Interleukin-33 Gene in Mammalian Cells[J]. China Biotechnology, 2019, 39(3): 46-55.
[15] Xi-wen JIANG,Zi-wei DONG,Yue LIU,Xiao-ya ZHU. Reserch Progress on Biomarkers and Precision Medicine[J]. China Biotechnology, 2019, 39(2): 74-81.